par Schaake-Koning, Caro C E C.;Dalesio, Otilia;Van Zandwijk, Nico;Bartelink, Harry;Van den Bogaert, Walter;Rodrigus, Patrick;Festen, Jan J M J.;Hoogenhout, Jaap;Van Houtte, Paul 
;Sculier, Jean-Paul ;Kirkpatrick, Anne;Koolen, Mia GJ J M.;Schuster-Uitterhoeve, Lon;Maat, Ben;Nijs, Arie;Renaud, Alain
Référence Lung cancer, 10, SUPPL. 1, page (S263-S270)
Publication Publié, 1994
;Sculier, Jean-Paul ;Kirkpatrick, Anne;Koolen, Mia GJ J M.;Schuster-Uitterhoeve, Lon;Maat, Ben;Nijs, Arie;Renaud, AlainRéférence Lung cancer, 10, SUPPL. 1, page (S263-S270)
Publication Publié, 1994
Article révisé par les pairs
| Résumé : | A three-arm randomized trial was performed to assess the acute and late toxicity and the impact on survival of the combination high-dose, split-course radiotherapy with 30 mg/m2 cisplatin (cDDP) weekly, with 6 mg/m2 cisplatin daily compared to radiotherapy alone in patients with non-small cell lung cancer (NSCLC). The study started in May 1984 and was closed in May 1989 after 331 patients were randomised. The analysis was performed after a minimum follow-up period of 22 months. Radiotherapy (RT) consisted of 30 Gy, 10 fractions, five fractions a week; then a 3-week split followed by 25 Gy in 10 fractions. © 1994. |
